Insulet Akcija

Insulet EBITDA

Vrijednost EBITDA (Заработак пре камата, пореза, амортизације и отписивања) od Insulet (PODD) na dan 20. авг 2026. je 473,80 М USD. Prethodne godine, EBITDA (Заработак пре камата, пореза, амортизације и отписивања) je bio 308,90 М USD — promjena od 53,38% (viši).

EBITDA

473,80 МUSD

YoY

53,38%

Zadnja ažuriranja:

EBITDA (Заработак пре камата, пореза, амортизације и отписивања) od Insulet je 2026 473,80 М USD. EBITDA (Заработак пре камата, пореза, амортизације и отписивања) od Insulet je bio 2025 308,90 М USD. Pad je time 53,38% viši u odnosu na prethodnu godinu.
Access this data via the Eulerpool API

Insulet Анализа акција

Šta radi Insulet? Insulet Corp is an American company that was founded in 2000 and is headquartered in Acton, Massachusetts. Its goal is to improve the quality of life for people with diabetes by developing innovative products that make living with this chronic disease easier. Insulet Corp is known for its product "OmniPod." The OmniPod is a wireless, portable disposable insulin pump system that offers an alternative option to traditional pumping and insulin delivery systems. The OmniPod system consists of two small devices: a pod worn on the skin and a PDM (Personal Diabetes Manager) that regulates insulin delivery. The pod contains an insulin reservoir that communicates wirelessly with the PDM. The insulin dose is administered directly into the body without needles or tubes. Insulet Corp is also introducing the "OmniPod DASH System." This new system combines the proven design of the OmniPod pod with a new color touchscreen handheld device that allows for even easier operation. The DASH system also offers the ability to control insulin dosing from a smartphone, which can be taken with diabetics wherever they go. The success of the OmniPod system has made Insulet Corp a leading company in the diabetes industry. The company has also developed and introduced products and services in other areas of diabetes treatment. Insulet Corp has developed another product called "Amigo." This product is a personalized travel and training program for people who require insulin. Amigo offers specialized and personalized training to support diabetics in managing complex situations. It also offers diet and exercise plans to make living with diabetes easier. Insulet Corp has also developed a software called "OmniPod Horizon." This software is a closed-loop system that automatically adjusts insulin dosing to keep blood sugar levels within the target range. The system is currently in the development phase and is expected to be released in 2020. Insulet Corp has also developed a program called the "OmniPod Partner Program," which targets doctors and pharmacists. The program provides training and educational materials for healthcare providers to help them better treat and manage their patients. Since 2009, Insulet Corp has been listed on the NASDAQ stock exchange and has continuously evolved since then. The company currently has over 1500 employees and operates in North America, Europe, and the Middle East. Insulet Corp is a company focused on the development of innovative, life-changing products and services. It is expected to continue to play a significant role in improving the quality of life for people with diabetes in the future. Insulet je jedna od najpopularnijih kompanija na Eulerpool.

Često postavljena pitanja o akciji Insulet

EBITDA (Заработак пре камата, пореза, амортизације и отписивања) kompanije Insulet iznosi 473,80 М USD u 2026. godini.

EBITDA (Заработак пре камата, пореза, амортизације и отписивања) od Insulet se promijenio sa 308,90 М USD na 473,80 М USD, što predstavlja promjenu od 53,38%. Vrijednost je viši nego prethodne godine.

Na Eulerpool-u možete pronaći potpuni historijski razvoj EBITDA (Заработак пре камата, пореза, амортизације и отписивања) Insulet od 2006. — sa godišnjim vrijednostima, grafikonima i detaljnom analizom.

EBITDA мери оперативну перформансу пре утицаја финансијске структуре, окружења пореза и не-готовинских отписивања.

EBITDA = EBIT + Амортизација и отписивање

EBITDA (Заработак пре камата, пореза, амортизације и отписивања)'s USD je ključan faktor za investitore. Promene u ovoj metrici mogu signalizirati poboljšane ili pogoršane fundamentalne faktore, direktno utiču na cenu akcije. Na Eulopoolu, možete pratiti EBITDA (Заработак пре камата, пореза, амортизације и отписивања)'s Insulet istorijski i u realnom vremenu.

Access this data via the Eulerpool API

Извештај о добити и губитку — Insulet

Sve ključne metrike — Insulet

Раст